Medical Device

jump stock

Leveljump Acquires 23.8% Interest in Shaw Lens and Shaw Vision

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that it has acquired 23.8% of the issued and outstanding shares of each of Shaw Vision Inc. ("Shaw Vision") and Shaw Lens Inc. ("Shaw Lens") from a minority shareholder (the "Shaw Acquisition").

The aggregate purchase price of the Shaw Acquisition is $129,500 and will be paid through issuance of 350,000 common shares of the Company ("JUMP Shares") at a deemed issuance price of $0.28 per JUMP Share and 350,000 non-transferable common share purchase warrants of the Company ("JUMP Warrants"). Each JUMP Warrant entitles the holder to purchase one common share of the Company at an exercise price of $0.30 per share prior to December 31, 2023. The Shaw Acquisition is an arm's length transaction. There are no finder's fees payable.

The Shaw Acquisition has been approved by the boards of Shaw Vision and Shaw Lens. Closing of the Shaw Acquisition is subject to the final consent of the TSX Venture Exchange.

All securities issued will be subject to a hold period of four months and one day pursuant to applicable securities laws.

Both Shaw Vision Inc. and Shaw Lens Inc. are Toronto-based privately owned federal corporations.

About Shaw Lens and Shaw Vision

Shaw Lens holds a U.S. patent protected lens technology that can solve a condition for people who wear glasses, known as aniseikonia. It is a condition that causes each eye to perceive the size of objects differently. Issues related can include headaches, double vision, disorientation or dizziness, tearing, eye pain or fatigue, sensitivity to light, visual acuity issues and trouble reading, as well as nausea…according to the Columbia University Department of Ophthalmology… "20-30% of the general spectacle wearing population may have a measurable amount of aniseikonia." The potential market size for corrective lenses for aniseikonia is over 800 million people that may be currently living with some degree of aniseikonia and its relative effects.

More information about Shaw can be found at www.shawlens.com

Quotes from JUMP CEO and Shaw CEO

"The Shaw Lens has proven to be effective with positive feedback from both doctors and patients," said Mitch Geisler, CEO. "We believe the keys to success are to work with the Shaw Lens management team, in order to expand the company and improve its operating systems. We would like to increase sales and marketing efforts to ensure that all optometrists are aware of the product and begin offering the lens to patients, and to back that up with a stable production effort and supply."

"The management at SHAW LENS looks forward to working with the resources at Leveljump to expand SHAW's customer base in all eyecare markets. The iseikonic lens technology is incredible -- lives are changed with the benefits of SHAW LENS." - Peter Shaw, CEO

Leveljump plans to be an active shareholder in Shaw and to assist Shaw in executing its business plan and expand the Shaw manufacturing capabilities in order to greatly expand Shaw revenues and grow its business.

About Leveljump Healthcare

LevelJump Healthcare Corp., (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) is building a national medical diagnostic imaging company and brand, primarily by providing teleradiology (remote radiology) services to its client hospitals and imaging centers. Additionally, JUMP plans to expand through the acquisition of independent healthcare facilities focused on diagnostic imaging as well as acquiring new disruptive imaging technologies.

ON BEHALF OF THE BOARD OF DIRECTORS OF

LevelJump Healthcare Corp.

Mitchell Geisler, Chief Executive Officer
info@leveljumphealthcare.com
(833) 840-2020

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/95031

News Provided by Newsfile via QuoteMedia

Alkaline Fuel Cell Power Corp. Announces the Closing of New Credit Facilities and Update on the Previously Announced Private Placement

Alkaline Fuel Cell Power Corp. Announces the Closing of New Credit Facilities and Update on the Previously Announced Private Placement

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) (" PWWR " or the " Company "), a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce that it has entered into a credit agreement (the " Credit Agreement ") with Juno Financial Group Corporation (" Juno ") for a fixed rate loan to the Company for a gross amount of approximately CAD $800,000 (the " Loan "). The entire Loan amount will be provided to the Company immediately and is expected to be used for general corporate purposes.

"We are pleased to be working with Juno with their cleantech experience, and we saw the loan as a more immediate opportunity to fund our current needs, thus postponing our private placement," stated Frank Carnevale, Chief Executive Officer."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Health Corporate Update - Earnings Advisory 2022 and 2023 Objectives

Avricore Health Corporate Update - Earnings Advisory 2022 and 2023 Objectives

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is entering the second year of a multi-year growth plan to bring HealthTab, its turnkey solution for point of care testing and data management, to more pharmacies across Canada and the world. As part of this effort the Company is pleased to provide insight into the successes of last year and lay out updates and objectives on further progress.

"Last year we set out bold targets and today we can demonstrate we've been able to achieve them," said Hector Bremner, CEO of Avricore Health Inc. "There's no doubt that we are poised for significant growth in 2023 and beyond."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
E-Power Resources Announces Director Change

E-Power Resources Announces Director Change

E-Power Resources Inc (CSE: EPR) ("E-Power" or the "Company") announces that Ms. Anna Oxenstierna has resigned from the board of directors of the Company, and the board has accepted her resignation. The Company thanks Ms. Oxenstierna for her contributions and wishes her well on her future endeavors.

The Company is currently in discussions with suitable candidates to replace Ms. Oxenstierna. An announcement will be made in due course.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Alkaline Fuel Cell Power Corp. Announces AGM Results

Alkaline Fuel Cell Power Corp. Announces AGM Results

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) ("AFCP" or the "Company") a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce the results of voting at its annual general meeting (" AGM ") of shareholders which was held on January 25, 2023 in person in Vancouver, British Columbia and by conference call (the " Meeting "). There were 19 shareholders represented in person or by proxy at the Meeting holding 2,423,369 common shares, representing 1.39% of the Company's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting is set out below:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Alkaline Fuel Cell Power Announces Resignation of Director

Alkaline Fuel Cell Power Announces Resignation of Director

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) ("AFCP" or the "Company") a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, announces the resignation of Joel Dumaresq as director, effective January 12, 2023. Mr. Dumaresq will remain as the Chief Financial Officer of the Company while the Company seeks a suitable replacement.

ABOUT Alkaline Fuel Cell Power CORP.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BriaCell CEO Letter to Shareholders

BriaCell CEO Letter to Shareholders

  • Positive FDA feedback on our pivotal study for lead clinical candidate Bria-IMT™ in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization.
  • Successful completion of the pivotal study could be followed by a Biologics License Application submission and commercialization.
  • Pivotal study's primary endpoint to be linked to survival improvement.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, today issues a letter to shareholders from Dr. William V. Williams, BriaCell's President and CEO.

Dear BriaCell Shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×